ApoE and cerebral insulin: Trafficking, receptors, and resistance
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Central nervous system (CNS) insulin resistance is associated with Alzheimer's disease (AD). In addition, the apolipoprotein E4 (apoE4) isoform is a risk factor for AD. The connection between these two factors in relation to AD is being actively explored. We summarize this literature with a focus on the transport of insulin and apoE across the blood-brain barrier (BBB) and into the CNS, the impact of apoE and insulin on the BBB, and the interactions between apoE, insulin, and the insulin receptor once present in the CNS. We highlight how CNS insulin resistance is apparent in AD and potential ways to overcome this resistance by repurposing currently approved drugs, with apoE genotype taken into consideration as the treatment response following most interventions is apoE isoform-dependent. This review is part of a special issue focusing on apoE in AD and neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · cited 2×
“Talbot et al confirmed these changes and further showed that signaling as induced by insulin was impaired in post mortem brain tissue from individuals without diabetes (Talbot et al., 2012).”
BackgroundSteen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 1×
“…studies involving post mortem tissue have revealed that the levels of protein or message for the insulin receptor and components of the insulin signaling pathway are decreased in AD brains (Chan et al., 2018; Liu et al., 2011; Rickle et al., 2004; Rivera et al., 2005; Steen et al., 2005).”
BackgroundThe role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366
Patterns of Brain Activation in People at Risk for Alzheimer's Disease
Bookheimer, S. Y., Strojwas, M. H., Cohen, M. S., Saunders, A. M., Pericak-Vance, M. A., Mazziotta, J. C., & Small, G. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008173430701 · Cited by 1,328 · cited 1×
“These effects and alterations in cerebral blood flow are not transient and are also seen in people during middle-age (Bookheimer et al., 2000).”
BackgroundApolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293
Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
Intranasal delivery of biologics to the central nervous system
Lochhead, J. J., & Thorne, R. G. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.002 · Cited by 1,214
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977
Association of apolipoprotein E genotypes with lipid levels and coronary risk
Bennet, A. M., Di Angelantonio, E., Ye, Z., Wensley, F., Dahlin, A., Ahlbom, A., Keavney, B., Collins, R., Wiman, B., de Faire, U., et al. (2007) · JAMA · doi:10.1001/jama.298.11.1300 · Cited by 794
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090106797 · Cited by 790
Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Holtzman, D. M., Herz, J., & Bu, G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006312 · Cited by 782
apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771 · cited 1×
“Specifically, apoE4 disrupts amyloid BBB efflux the most (Deane et al., 2008) and primarily impacts BBB integrity by contributing to BBB anomalies (Alata et al., 2015).”
BackgroundRivera, E. J., Goldin, A., Fulmer, N., Tavares, R., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8304 · Cited by 723 · cited 1×
“…studies involving post mortem tissue have revealed that the levels of protein or message for the insulin receptor and components of the insulin signaling pathway are decreased in AD brains (Chan et al., 2018; Liu et al., 2011; Rickle et al., 2004; Rivera et al., 2005; Steen et al., 2005).”
BackgroundIntranasal insulin improves memory in humans
Benedict, C., Hallschmid, M., Hatke, A., Schultes, B., Fehm, H. L., Born, J., & Kern, W. (2004) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2004.04.003 · Cited by 699
Vascular contributions to cognitive impairment and dementia including Alzheimer's disease
Snyder, H. M., Corriveau, R. A., Craft, S., Faber, J. E., Greenberg, S. M., Knopman, D., Lamb, B. T., Montine, T. J., Nedergaard, M., Schaffer, C. B., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.008 · Cited by 603
ApoE genotype accounts for the vast majority of AD risk and AD pathology
Raber, J., Huang, Y., & Ashford, J. W. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.023 · Cited by 599
Self-citationApolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS
Mahley, R. W., Weisgraber, K. H., & Huang, Y. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800069-jlr200 · Cited by 580
Craft, S., Peskind, E., Schwartz, M. W., Schellenberg, G. D., Raskind, M., & Porte, D. (1998) · Neurology · doi:10.1212/wnl.50.1.164 · Cited by 560 · cited 2×
“These four lines of evidence are considered below. i. Decreased CSF/serum ratio A decreased CSF/serum ratio for insulin has been reported in aged and AD subjects (Craft et al., 1998; Sartorius et al., 2015).”
BackgroundMemory improvement following induced hyperinsulinemia in Alzheimer’s disease
Craft, S., Newcomer, J., Kanne, S., Dagogo-Jack, S., Cryer, P., Sheline, Y., Luby, J., Dagogo-Jack, A., & Alderson, A. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(95)02002-0 · Cited by 538
Baura, G. D., Foster, D. M., Porte, D., Kahn, S. E., Bergman, R. N., Cobelli, C., & Schwartz, M. W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116773 · Cited by 489
The source of cerebral insulin
Banks, W. A. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.040 · Cited by 489 · cited 1×
“…by impacting signal transduction pathways involved in neuronal survival, synaptic maintenance, dendritic arbor development, cognition, neuronal circuitry formation, and BBB transporter expression/localization (Banks, 2004; Banks et al., 2012; Schulingkamp et al., 2000; Stranahan et al., 2008).”
BackgroundSelf-citationInteractions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier
Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480
Reiman, E. M., Caselli, R. J., Chen, K., Alexander, G. E., Bandy, D., & Frost, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061509598 · Cited by 467
Heindel, J. J., & Vandenberg, L. N. (2015) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000191 · Cited by 439
Enhancement of Memory in Alzheimer Disease With Insulin and Somatostatin, but Not Glucose
Craft, S., Asthana, S., Newcomer, J. W., Wilkinson, C. W., Matos, I. T., Baker, L. D., Cherrier, M., Lofgreen, C., Latendresse, S., Petrova, A., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1135 · Cited by 312
Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes
Zhao, N., Liu, C.-C., Van Ingelgom, A. J., Martens, Y. A., Linares, C., Knight, J. A., Painter, M. M., Sullivan, P. M., & Bu, G. (2017) · Neuron · doi:10.1016/j.neuron.2017.09.003 · Cited by 289
Insulin in the Cerebrospinal Fluid
MARGOLIS, R. U., & ALTSZULER, N. (1967) · Nature · doi:10.1038/2151375a0 · Cited by 278 · cited 1×
“primarily derived from blood insulin, which has been transported across the blood-brain barrier (BBB) (Banks et al., 1997a; Margolis and Altszuler, 1967; Woods and Porte, 1977).”
BackgroundNishitsuji, K., Hosono, T., Nakamura, T., Bu, G., & Michikawa, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.225532 · Cited by 275
Cerebrovascular Effects of Apolipoprotein E: Implications for Alzheimer Disease
Zlokovic, B. V. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.2152 · Cited by 263
Marks, D. R., Tucker, K., Cavallin, M. A., Mast, T. G., & Fadool, D. A. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1350-09.2009 · Cited by 242
The role of APOE in cerebrovascular dysfunction
Tai, L. M., Thomas, R., Marottoli, F. M., Koster, K. P., Kanekiyo, T., Morris, A. W. J., & Bu, G. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1547-z · Cited by 231
Banks, W. A., Jaspan, J. B., & Kastin, A. J. (1997) · Peptides · doi:10.1016/s0196-9781(97)00198-8 · Cited by 219
Self-citationCerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease
Cruchaga, C., Kauwe, J. S. K., Nowotny, P., Bales, K., Pickering, E. H., Mayo, K., Bertelsen, S., Hinrichs, A., Fagan, A. M., Holtzman, D. M., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds296 · Cited by 207
Insulin Regulates Brain Function, but How Does It Get There?
Gray, S. M., Meijer, R. I., & Barrett, E. J. (2014) · Diabetes · doi:10.2337/db14-0340 · Cited by 206
Obesity, diabetes and the central nervous system
Porte Jr., D., Seeley, R. J., Woods, S. C., Baskin, D. G., Figlewicz, D. P., & Schwartz, M. W. (1998) · Diabetologia · doi:10.1007/s001250051002 · Cited by 186
Thorne, R. G., Hrabětová, S., & Nicholson, C. (2004) · Journal of Neurophysiology · doi:10.1152/jn.00352.2004 · Cited by 168
Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond
Pendse, A. A., Arbones-Mainar, J. M., Johnson, L. A., Altenburg, M. K., & Maeda, N. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800070-jlr200 · Cited by 155
Insulin metabolism in Alzheimer’s disease differs according to apolipoprotein E genotype and gender
Craft, S., Asthana, S., Schellenberg, G., Cherrier, M., Baker, L. D., Newcomer, J., Plymate, S., Latendresse, S., Petrova, A., Raskind, M., et al. (1999) · Neuroendocrinology · doi:10.1159/000054469 · Cited by 154
Cell-specific production, secretion, and function of apolipoprotein E
Kockx, M., Traini, M., & Kritharides, L. (2018) · Journal of Molecular Medicine · doi:10.1007/s00109-018-1632-y · Cited by 124
Habenular TCF7L2 links nicotine addiction to diabetes
Duncan, A., Heyer, M. P., Ishikawa, M., Caligiuri, S. P. B., Liu, X.-A., Chen, Z., Micioni Di Bonaventura, M. V., Elayouby, K. S., Ables, J. L., Howe, W. M., et al. (2019) · Nature · doi:10.1038/s41586-019-1653-x · Cited by 119
Impairment of the Blood–Nerve and Blood–Brain Barriers in Apolipoprotein E Knockout Mice
Fullerton, S. M., Shirman, G. A., Strittmatter, W. J., & Matthew, W. D. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7631 · Cited by 117
Safety of intranasal human insulin: A review
Schmid, V., Kullmann, S., Gfrörer, W., Hund, V., Hallschmid, M., Lipp, H., Häring, H., Preissl, H., Fritsche, A., & Heni, M. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13279 · Cited by 110
Johnson, L. A., Olsen, R. H. J., Merkens, L. S., DeBarber, A., Steiner, R. D., Sullivan, P. M., Maeda, N., & Raber, J. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.12.016 · Cited by 107
Self-citationBarone, E., Di Domenico, F., Cassano, T., Arena, A., Tramutola, A., Lavecchia, M. A., Coccia, R., Butterfield, D. A., & Perluigi, M. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.12.012 · Cited by 100
APOE related alterations in cerebral activation even at college age
Scarmeas, N. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.053645 · Cited by 97
Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease
Barone, E., Tramutola, A., Triani, F., Calcagnini, S., Di Domenico, F., Ripoli, C., Gaetani, S., Grassi, C., Butterfield, D. A., Cassano, T., et al. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1231-5 · Cited by 86
Iron Deposition Leads to Hyperphosphorylation of Tau and Disruption of Insulin Signaling
Wan, W., Cao, L., Kalionis, B., Murthi, P., Xia, S., & Guan, Y. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00607 · Cited by 84 · cited 1×
“Various studies have implicated amyloid , tau, iron, and other factors (Bloom et al., 2018; Wan et al., 2019).”
BackgroundErratum: Thyroid hormone transporters—functions and clinical implications
Bernal, J., Guadaño-Ferraz, A., & Morte, B. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.186 · Cited by 63
A Dietary Treatment Improves Cerebral Blood Flow and Brain Connectivity in Aging apoE4 Mice
Wiesmann, M., Zerbi, V., Jansen, D., Haast, R., Lütjohann, D., Broersen, L. M., Heerschap, A., & Kiliaan, A. J. (2016) · Neural Plasticity · doi:10.1155/2016/6846721 · Cited by 60
Banks, W. A., Dohgu, S., Lynch, J. L., Fleegal-DeMotta, M. A., Erickson, M. A., Nakaoke, R., & Vo, T. Q. (2008) · Endocrinology · doi:10.1210/en.2007-1091 · Cited by 57
Self-citationJohnson, L. A., Torres, E. R., Weber Boutros, S., Patel, E., Akinyeke, T., Alkayed, N. J., & Raber, J. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17746186 · Cited by 56
Self-citationReduced brain insulin signaling: A seminal process in Alzheimer's disease pathogenesis
Bloom, G. S., Lazo, J. S., & Norambuena, A. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.016 · Cited by 44
Routes for the delivery of insulin to the central nervous system: A comparative review
Rhea, E. M., Salameh, T. S., & Banks, W. A. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2018.11.007 · Cited by 43
Self-citationChan, E. S., Chen, C., Cole, G. M., & Wong, B.-S. (2015) · Scientific Reports · doi:10.1038/srep13842 · Cited by 29
Cited by
Kellar, D., & Craft, S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30231-3 · Cited by 832
Healthy aging and the blood–brain barrier
Banks, W. A., Reed, M. J., Logsdon, A. F., Rhea, E. M., & Erickson, M. A. (2021) · Nature Aging · doi:10.1038/s43587-021-00043-5 · Cited by 292
Self-citationFernández-Calle, R., Konings, S. C., Frontiñán-Rubio, J., García-Revilla, J., Camprubí-Ferrer, L., Svensson, M., Martinson, I., Boza-Serrano, A., Venero, J. L., Nielsen, H. M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00566-4 · Cited by 278
The Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer’s Disease
Kloske, C. M., & Wilcock, D. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00754 · Cited by 152
Insulin Resistance in Peripheral Tissues and the Brain: A Tale of Two Sites
Rhea, E. M., Banks, W. A., & Raber, J. (2022) · Biomedicines · doi:10.3390/biomedicines10071582 · Cited by 76
“For a review about apoE and cerebral insulin, please see [15].”
BackgroundSelf-citation
Metadata
- Authors
- Rhea, E. M., Raber, J., & Banks, W. A.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 137
- Pages
- 104755
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W3002934640
- Cited by
- 47
- References
- 57
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.